Laparoscopic management of pelvic organ prolapse recurrence after open sacrocervicopexy

Redo laparoscopic sacrocolpopexy for POP recurrence: Is it the right call?

OBJECTIVES

As Laparoscopic Sacrocolpopexy (LSCP) has proven to be the gold-standard for treating Pelvic Organ Prolapse, management of recurrence after its failure is a challenge with upcoming interest. In these patients, repeat LSCP might represent a suitable surgical choice.

STUDY DESIGN

We present a retrospective observational study analysing safety, feasibility and outcomes of Redo LSCP. Data of 20 patients with POP recurrence who underwent previous sacrocolpopexy were recruited, and all successfully underwent a repeat LSCP.

RESULTS

Median 24-months follow-up demonstrated a statistically significant improvement of objective and subjective outcome. No intra and postoperative complications were noted. Anatomical cure rate was 95%. Subjective cure rate was 100%, with a statistically significant POP symptoms resolution and improvement of voiding and storage symptoms. We compared perioperative data and outcome of Redo patients to a population who underwent LSCP for a first-time diagnosed POP. The findings demonstrated that surgery did not differ from standard procedure in terms of intra/postoperative complications, hospital stay, blood loss, except for operative time.

CONCLUSIONS

Minimally invasive Redo LSCP appears to be a safe and effective procedure in treating recurrent and symptomatic Pelvic Organ Prolapse. Our series shows low recurrence rates, comparable to data from patients who underwent their primary surgery for POP.

Robot-assisted Sacrocolpopexy for Recurrent Pelvic Organ Prolapse: Insights for a Challenging Surgical Setting

BACKGROUND

No consensus exists regarding the management of recurrent pelvic organ prolapse (POP). The aim of this study was to evaluate robot-assisted laparoscopic sacrocolpopexy for recurrent pelvic organ prolapse (POP), and to investigate postoperative outcomes.

METHODS

We conducted a single-centre retrospective study including 10 consecutive patients who underwent a robot-assisted sacrocolpopexy for symptomatic POP recurrence from February 2017 to December 2019. Recurrence rates and patient satisfaction, measured by the Pelvic Floor Impact Questionnaire (PFIQ-7) were recorded.

RESULTS

Median age was 57 years (IQR: 54-67). No intraoperative complications were reported. The median hospital stay after surgery was 2 nights (IQR: 1-4). Two patients (20%) experienced early recurrence: at 1 month for one and at 4.5 months for the other. The median follow-up for the remaining eight patients was 18 months (IQR: 12-23). Among the recurrence-free patients, the median PFIQ-7 score was 11.4 at 12 months.

CONCLUSIONS

Robot-assisted sacrocolpopexy is feasible and safe for the management of POP recurrence, with a high patient satisfaction.